Hall 2002.

Methods	Study design: Randomized controlled trial Country: USA Recruitment: Community volunteers. Exclusion criteria included current MDD Group size: 3 ‐ 11
Participants	220 smokers of ≥ 10 cpd 40% ‐ 47% women, av. age 37 ‐ 43, av. cpd 20 ‐ 23; 33% had history of MDD Therapists: Masters‐level counsellors
Interventions	3 x 2 factorial design with pharmacotherapies: bupropion, nortriptyline, or placebo 1. Medical Management (MM) control: physician advice, S‐H, 10 ‐ 20 mins 1st visit, 5 mins at 2, 6, 11 wks) 2. Psychological Intervention (PI) as MM plus 5 x 90‐min group sessions at 4, 5, 5, 7, 11 wks)
Outcomes	Prolonged abstinence at 1 yr (47 wks post‐quit date). PPA also reported Validation: CO ≤ 10 ppm, urine cotinine ≤ 60 ng/mL
Notes	Comparison 1.3, group versus physician advice No significant interaction between pharmacotherapy and behaviour therapy, so pharmacotherapy arms collapsed in analysis
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomized, method not specified, "double blind"
Allocation concealment (selection bias)	Unclear risk	No details given
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Biochemical validation of abstinence
Incomplete outcome data (attrition bias) All outcomes	Low risk	19% lost to follow‐up at 1 yr, no difference by group, included in ITT analysis